

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/738,049	12/15/2000	David R. Kaplan	071957-0903	2323	
23620 75	90 03/19/2002				
FOLEY & LARDNER			EXAMINER		
402 WEST BRO 23RD FLOOR		GABEL, GAILENE			
SAN DIEGO, C	A 92101		ART UNIT	PAPER NUMBER	
			1641	Ø.	
			DATE MAILED: 03/19/2002	U	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati n No.		Applicant(s)				
•		09/738,049		KAPLAN, DAVID R.				
	Office Action Summary	Examiner		Art Unit				
		Gailene R. Gabel		1641				
	The MAILING DATE f this communicati n appears on the cover sheet with the c rrespondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
1)⊠	1)⊠ Responsive to communication(s) filed on <u>15 December 2000</u> .							
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This action is non-final.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims	parte Queyre,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
4)⊠	4)⊠ Claim(s) <u>1-61</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)□	S) Claim(s) is/are allowed.							
6)□	6) Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
8) Claim(s) <u>1-61</u> are subject to restriction and/or election requirement.								
	on Papers The appeification is objected to by the Evaminer							
9) ☐ The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
10)	Applicant may not request that any objection to the	•	•					
11)[7]	The proposed drawing correction filed on		·					
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 								
Attachment(s)								
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲	-	PTO-413) Paper No(s) stent Application (PTO-152)				

Application/Control Number: 09/738,049

Art Unit: 1641

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-33, drawn to method of detecting the presence of intracellular analyte in one or more cells, classified in class 435, subclass 7.2, for example.
 - II. Claims 34-37, drawn to composition having a binding partner in a medium comprising serum, classified in class 436, subclass 8, for example.
 - III. Claims 38-45, drawn to composition having tyramide and an enzyme in a medium comprising aprotic solvent, classified in class 435, subclass 176, for example.
 - IV. Claims 46-51, drawn to composition having tyramide and an enzyme in a medium comprising peptides, classified in class 530, subclass 324, for example.
 - V. Claims 52-61, drawn to composition having a hapten, antibody, and enzyme, classified in class 435, subclass 7.72 for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of

Application/Control Number: 09/738,049

Art Unit: 1641

using that product (MPEP § 806.05(h)). In the instant case, the cells in the method of Invention I can be reacted with intracellular analyte specific reporter molecules for manual microscopic detection of intracellular analytes in a sample.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the composition of Invention III can be incorporated with an unknown compound for use in evaluating its effects on the distribution and activity of intracellular analyte in a live cell.

Inventions I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the composition of Invention IV can be used in evaluating dynamic protein binding interaction and kinetics of intracellular analyte in a live cell.

Inventions I and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the cells in the method of

Application/Control Number: 09/738,049

Art Unit: 1641

Invention I can be reacted with intracellular analyte specific reporter molecules for automated cell-based high field microscopic detection of intracellular analytes in a sample.

Inventions II, III, IV and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different compositions in Inventions II, III, IV, and V have different modes of operation and different effects in that the composition of Invention II has a binding partner in a medium comprising 50% serum for use in detecting an analyte on interest, the composition of Invention III has a labeled tyramide, enzyme, and medium comprising 5% aprotic solvent for use in detecting an analyte of interest, the composition of Invention IV has a labeled tyramide, enzyme, and medium comprising peptides for use in detecting an analyte of interest, and the composition of Invention V has hapten, antibody, and enzyme for use in detecting an analyte of interest.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Furthermore, because the search required for Group I is not required for Group II, and the search for Group III is not required for Group IV and further not required for Group V, restriction for examination purposes as indicated is proper. Literature search for each method and each composition is distinct since the structural requirements of each invention are different.

Art Unit: 1641

While searches would be expected to overlap, there is no reason to expect the searches to be coextensive.

2. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gailene R Gabel whose telephone number is (703) 305-9297. The examiner can normally be reached on Monday-Thursday 6:00 AM to 3:30 PM and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (703) 305-3399. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 305-3014 for After Final communications.

Art Unit: 1641

Page 6

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Gailene R. Gabel March 15, 2002

CHRISTOPHER L. CHIN PRIMARY EXAMINER

GROUP 1800-1641

Christyph L. Chi